Acadia Healthcare Company, Inc. (NASDAQ:ACHC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday, August 1st.
According to Zacks, “Acadia Healthcare’s second-quarter 2017 earnings surpassed the Zacks Consensus Estimate, mainly driven by an increase in same facility revenue, patient days and revenue per patient day. The company is well positioned for long-term growth on the back of its inorganic strategies. Its latest Priory acquisition has substantially enhanced its asset base, making it the largest independent provider of mental health services in the U.K. Its mixed product portfolio has helped in intensifying business risk. The company’s strong balance sheet, with increasing cash flow is another positive. Year to date, shares of Acadia Healthcare have outperformed the industry. But the company suffers from high debt, escalating interest expenses and foreign exchange fluctuation. Substantial integration risks associated with its frequent acquisitions are major headwinds.”
ACHC has been the subject of several other research reports. Mizuho upped their price target on Acadia Healthcare from $57.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 28th. BidaskClub raised Acadia Healthcare from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Craig Hallum reissued a “buy” rating and issued a $65.00 price objective (up previously from $52.00) on shares of Acadia Healthcare in a research report on Monday, July 31st. Leerink Swann cut Acadia Healthcare from an “outperform” rating to a “market perform” rating in a research report on Monday, May 15th. Finally, UBS AG reissued a “positive” rating and issued a $60.00 price objective (up previously from $54.00) on shares of Acadia Healthcare in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $59.21.
Shares of Acadia Healthcare (NASDAQ ACHC) opened at 46.90 on Tuesday. Acadia Healthcare has a 12-month low of $32.54 and a 12-month high of $54.34. The firm has a market cap of $4.12 billion, a P/E ratio of 515.38 and a beta of 1.15. The stock has a 50 day moving average price of $50.51 and a 200 day moving average price of $45.06.
Acadia Healthcare (NASDAQ:ACHC) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Acadia Healthcare had a return on equity of 8.69% and a net margin of 0.30%. The business had revenue of $715.90 million during the quarter, compared to the consensus estimate of $717.38 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. Acadia Healthcare’s revenue was down 5.4% compared to the same quarter last year. On average, equities analysts expect that Acadia Healthcare will post $2.45 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Rating Lowered to Hold at Zacks Investment Research” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/19/acadia-healthcare-company-inc-nasdaqachc-downgraded-by-zacks-investment-research-updated-updated.html.
In related news, Director William Grieco sold 2,000 shares of the stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $51.71, for a total transaction of $103,420.00. Following the sale, the director now owns 45,013 shares of the company’s stock, valued at approximately $2,327,622.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Reeve B. Waud sold 50,000 shares of the stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $45.09, for a total value of $2,254,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,138,347 shares of company stock worth $105,486,669 in the last ninety days. Insiders own 11.10% of the company’s stock.
A number of hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its stake in shares of Acadia Healthcare by 43.9% in the first quarter. Russell Investments Group Ltd. now owns 221,649 shares of the company’s stock worth $9,664,000 after buying an additional 67,665 shares during the period. First Mercantile Trust Co. boosted its stake in shares of Acadia Healthcare by 49.3% in the first quarter. First Mercantile Trust Co. now owns 10,175 shares of the company’s stock worth $443,000 after buying an additional 3,359 shares during the period. Mesirow Financial Investment Management Equity Management bought a new stake in shares of Acadia Healthcare during the first quarter worth about $17,724,000. Nationwide Fund Advisors boosted its stake in shares of Acadia Healthcare by 683.9% in the first quarter. Nationwide Fund Advisors now owns 75,852 shares of the company’s stock worth $3,307,000 after buying an additional 66,176 shares during the period. Finally, Parametrica Management Ltd bought a new stake in shares of Acadia Healthcare during the first quarter worth about $291,000.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Acadia Healthcare Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acadia Healthcare Company Inc. and related companies.